Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Annals of Surgical Oncology|March 3, 2015
Pathological complete response in neoadjuvant treatment of breast cancerPatricia Cortazar, Charles E Geyer
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Neoadjuvant breast cancer therapy and drug developmentPatricia Cortazar, Paul G Kluetz
The Oncologist|December 15, 2010
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)Martin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|March 5, 2010
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumorsMartin H Cohen, Patricia Cortazar, Robert Justice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Overestimation of the effect size in group sequential trialsJenny J Zhang, Gideon M Blumenthal, Kun He, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2014
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancerLaleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, et al.
Cancer Treatment Reviews|June 17, 2021
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working GroupStuart M Lichtman, R Donald Harvey, Marie-Anne Damiette Smit, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Pageof 2